Citizens Financial Group Inc. RI Has $3.28 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Citizens Financial Group Inc. RI decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,766 shares of the company’s stock after selling 686 shares during the period. Citizens Financial Group Inc. RI’s holdings in Zoetis were worth $3,276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ZTS. Asset Dedication LLC lifted its position in shares of Zoetis by 4.8% during the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after acquiring an additional 54 shares during the period. Forza Wealth Management LLC raised its position in Zoetis by 1.8% during the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after purchasing an additional 58 shares in the last quarter. Cherry Creek Investment Advisors Inc. lifted its stake in Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the last quarter. L. Roy Papp & Associates LLP boosted its holdings in shares of Zoetis by 2.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after purchasing an additional 60 shares in the last quarter. Finally, Grove Bank & Trust raised its stake in Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.6 %

Shares of NYSE:ZTS opened at $176.71 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business’s 50-day moving average is $185.90 and its 200-day moving average is $180.45. The company has a market capitalization of $79.73 billion, a price-to-earnings ratio of 33.22, a P/E/G ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.36 earnings per share. Equities research analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus lifted their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.